thiazoles has been researched along with Parkinson Disease, Secondary in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (52.17) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 6 (26.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Ghoorah, D; Hou, L; Huang, J; Jia, M; Lin, Z; Liu, L; Luo, Z; Wang, T; Xiong, J; Xiong, N; Zhang, X; Zhang, Z | 1 |
| Al-Jadiri, A; Azzo, S; Carbon, M; Correll, CU; Kane, JM; Kapoor, S; Saito, E; Sarkaria, T; Sheridan, E | 1 |
| Buhl, D; Lamkin, S | 1 |
| Brotchie, JM; Fox, SH; Johnston, TH; McIldowie, MJ; Piggott, MJ | 1 |
| Biswas, S; Dutta, AK; Le, W; Li, C; Li, X | 1 |
| Chien, WL; Fu, WM; Hung, SY; Kang, KH; Lee, MJ; Lee, TR | 1 |
| Harish, G; Mahadevan, A; Shankar, SK; Srinivas Bharath, MM | 1 |
| Bilal, L; Gasper, JJ; Ndlela, JC; Tsai, C | 1 |
| Schindehütte, J; Trenkwalder, C | 1 |
| de Oliveira Lança, G; Hara, C; Kascher, GG; Magalhães Scoralick, F; Ramos, MG; Rocha, FL; Santos, MA | 1 |
| Boireau, A; Bordier, F; Doble, A; Dubédat, P; Durand, G; Meunier, M; Miquet, JM; Peny, C | 1 |
| Boireau, A; Doble, A; Dubédat, P; Meunier, M; Miquet, JM | 1 |
| Benazzouz, A; Boireau, A; Boraud, T; Dubédat, P; Gross, C; Stutzmann, JM | 1 |
| Barnéoud, P; Boireau, A; Doble, A; Dubédat, P; Mazadier, M; Miquet, JM; Parmentier, S | 1 |
| Domino, EF; Kohno, Y; Ni, L; Sasa, M; Zhang, H | 2 |
| Brouillet, E; Guyot, MC; Hantraye, P; Mary, V; Palfi, S; Peschanski, M; Riche, D; Stutzmann, JM; Wahl, F | 1 |
| Bennett, JP; Cassarino, DS; Fall, CP; Smith, TS | 1 |
| Gleason, WB; Johnson, RL; Khalil, EM; Mishra, RK; Ojala, WH; Pradhan, A | 1 |
| Lorenc-Koci, E; Wolfarth, S | 1 |
| Giardiniere, M; Morain, P; Schneider, JS | 1 |
| Mierau, J; Schingnitz, G | 1 |
| Colpaert, FC; Degryse, AD; Van Craenendonck, HV | 1 |
1 trial(s) available for thiazoles and Parkinson Disease, Secondary
| Article | Year |
|---|---|
An exploratory open-label trial of ziprasidone for the treatment of behavioral and psychological symptoms of dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Disorders of Excessive Somnolence; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Male; Mental Disorders; Middle Aged; Parkinson Disease, Secondary; Piperazines; Thiazoles | 2006 |
22 other study(ies) available for thiazoles and Parkinson Disease, Secondary
| Article | Year |
|---|---|
The role of autophagy in Parkinson's disease: rotenone-based modeling.
Topics: Apoptosis; Autophagy; Blotting, Western; Cell Death; Cell Line; Cell Proliferation; Coloring Agents; Dose-Response Relationship, Drug; Down-Regulation; Humans; Immunohistochemistry; Membrane Potential, Mitochondrial; Microscopy, Electron, Transmission; Microtubule-Associated Proteins; Parkinson Disease, Secondary; Reactive Oxygen Species; Rotenone; Tetrazolium Salts; Thiazoles; Uncoupling Agents | 2013 |
Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Male; Mental Disorders; Multivariate Analysis; New York; Olanzapine; Parkinson Disease, Secondary; Piperazines; Prospective Studies; Quetiapine Fumarate; Regression Analysis; Risperidone; Thiazoles | 2015 |
Extrapyramidal side effects: could you identify them in the emergency department?
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Dystonia; Emergency Nursing; Emergency Treatment; Female; Humans; Infant; Male; Muscle Rigidity; Nursing Assessment; Parkinson Disease, Secondary; Piperazines; Risk Factors; Risperidone; Syndrome; Thiazoles | 2009 |
Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary; Piperidines; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Thiazoles | 2010 |
Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin.
Topics: Acetylcysteine; Animals; Benzothiazoles; Biphenyl Compounds; Brain; Brain Chemistry; Brain-Derived Neurotrophic Factor; Cysteine Proteinase Inhibitors; Dopamine Agonists; Dopamine Antagonists; Enzyme-Linked Immunosorbent Assay; Glial Cell Line-Derived Neurotrophic Factor; Immunohistochemistry; Indans; Locomotion; Male; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; Neostriatum; Neuroprotective Agents; Parkinson Disease, Secondary; Piperazines; Postural Balance; Proteasome Endopeptidase Complex; Receptors, Dopamine D3; Thiazoles | 2010 |
Impairment of oxidative stress-induced heme oxygenase-1 expression by the defect of Parkinson-related gene of PINK1.
Topics: 1-Methyl-4-phenylpyridinium; Adenoviridae; Benzimidazoles; Blotting, Western; Cell Line; Cell Survival; Cloning, Molecular; Coloring Agents; Dopamine; Fluorescent Antibody Technique; Fluorescent Dyes; Gene Expression Regulation; Genetic Vectors; Heme Oxygenase-1; HSP90 Heat-Shock Proteins; Humans; L-Lactate Dehydrogenase; Mutation; Oxidative Stress; Parkinson Disease, Secondary; Protein Kinases; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA; Tetrazolium Salts; Thiazoles | 2011 |
Alteration in glutathione content and associated enzyme activities in the synaptic terminals but not in the non-synaptic mitochondria from the frontal cortex of Parkinson's disease brains.
Topics: Adult; Aged; Biomarkers; Blotting, Western; Citrate (si)-Synthase; Coloring Agents; Electrophoresis, Polyacrylamide Gel; Female; Frontal Lobe; Glutathione; Glutathione Reductase; Glutathione Transferase; Humans; Immunohistochemistry; Malate Dehydrogenase; Male; Middle Aged; Mitochondria; Neuropil; Nitrates; Oxidants; Parkinson Disease, Secondary; Presynaptic Terminals; Protein Carbonylation; Succinate Dehydrogenase; Superoxide Dismutase; Tetrazolium Salts; Thiazoles | 2013 |
Parkinsonism with intramuscular ziprasidone.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Humans; Injections, Intramuscular; Male; Middle Aged; Parkinson Disease, Secondary; Piperazines; Schizophrenia, Paranoid; Thiazoles; Violence | 2005 |
Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Laughter; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Piperazines; Psychoses, Substance-Induced; Quetiapine Fumarate; Thiazoles | 2007 |
Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dopamine; Homovanillic Acid; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Riluzole; Thiazoles | 1994 |
Riluzole and experimental parkinsonism: partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Excitatory Amino Acid Antagonists; Extracellular Space; Homovanillic Acid; Male; Parkinson Disease, Secondary; Rats; Riluzole; Thiazoles | 1994 |
Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study.
Topics: Animals; Antiparkinson Agents; Dopamine; Electromyography; Excitatory Amino Acid Antagonists; Macaca mulatta; MPTP Poisoning; Muscle Rigidity; Neuroprotective Agents; Parkinson Disease, Secondary; Pilot Projects; Riluzole; Sodium Channels; Thiazoles | 1995 |
Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apomorphine; Brain Chemistry; Central Nervous System Stimulants; Conditioning, Operant; Dopamine Agonists; Female; Male; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Riluzole; Stereotyped Behavior; Substantia Nigra; Sympatholytics; Thiazoles | 1996 |
Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Azepines; Basal Ganglia Diseases; Behavior, Animal; Benzazepines; Benzothiazoles; Dopamine Agents; Dopamine Agonists; Drug Interactions; Female; Macaca nemestrina; MPTP Poisoning; Parkinson Disease, Secondary; Pramipexole; Sleep; Thiazoles | 1997 |
Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration.
Topics: Acetylcholinesterase; Animals; Antiparkinson Agents; Apomorphine; Caudate Nucleus; Corpus Striatum; Movement Disorders; Nerve Degeneration; Neurons; Neuroprotective Agents; Neurotoxins; Nitro Compounds; Papio; Parkinson Disease, Secondary; Propionates; Putamen; Riluzole; Thiazoles | 1997 |
Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Agents; Benzothiazoles; Biological Transport; Calcium; Corpus Striatum; Dopamine Agents; Humans; Ion Channel Gating; Liver; Male; Microdialysis; Mitochondria; Neuroblastoma; Neuroprotective Agents; Neurotoxins; Parkinson Disease, Secondary; Phosphorus; Porins; Pramipexole; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Thiazoles; Tumor Cells, Cultured | 1998 |
Effects of pramipexole on contraversive rotation and functional motor impairments in 1-methyl-4-phenyl1,2,3, 6-tetrahydropyridine-induced chronic hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzothiazoles; Dopamine Agents; Dose-Response Relationship, Drug; Eating; Female; Macaca nemestrina; Motor Activity; Parkinson Disease, Secondary; Pramipexole; Rotation; Stereotyped Behavior; Thiazoles; Volition | 1998 |
Synthesis and dopamine receptor modulating activity of substituted bicyclic thiazolidine lactam peptidomimetics of L-prolyl-L-leucyl-glycinamide.
Topics: Animals; Crystallography, X-Ray; Dopamine Agents; Lactams; Male; Models, Molecular; Molecular Mimicry; Molecular Structure; MSH Release-Inhibiting Hormone; Oxidopamine; Parkinson Disease, Secondary; Pyrrolidines; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Structure-Activity Relationship; Thiazoles; Thiazolidines | 1999 |
Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats.
Topics: alpha-Methyltyrosine; Animals; Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; Electromyography; Haloperidol; Male; Muscle Rigidity; Muscle, Skeletal; Parkinson Disease, Secondary; Pramipexole; Rats; Rats, Wistar; Reserpine; Thiazoles; Treatment Outcome | 1999 |
Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cognition Disorders; Conditioning, Operant; Discrimination Learning; Dopamine Agents; Indoles; Macaca fascicularis; Male; Parkinson Disease, Secondary; Pattern Recognition, Visual; Prolyl Oligopeptidases; Psychomotor Performance; Serine Endopeptidases; Serine Proteinase Inhibitors; Thiazoles; Thiazolidines | 2002 |
Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzothiazoles; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Exploratory Behavior; Female; Haloperidol; Male; Medial Forebrain Bundle; Mice; Motor Activity; Norepinephrine; Parkinson Disease, Secondary; Pramipexole; Rats; Receptors, Dopamine D2; Rotation; Stereoisomerism; Synapses; Thiazoles | 1992 |
Effects of an alpha 2 antagonist in a 20-year-old Java monkey with MPTP-induced parkinsonian signs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic alpha-Antagonists; Animals; Blinking; Locus Coeruleus; Macaca fascicularis; Neurons; Parkinson Disease, Secondary; Piperidines; Thiazoles; Tremor | 1991 |